Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1486-94. doi: 10.1161/ATVBAHA.114.303678. Epub 2014 May 1.

Abstract

Objective: Small GTPase Ras-related protein 1 (Rap1b) controls several basic cellular phenomena, and its deletion in mice leads to several cardiovascular defects, including impaired adhesion of blood cells and defective angiogenesis. We found that Rap1b(-/-) mice develop cardiac hypertrophy and hypertension. Therefore, we examined the function of Rap1b in regulation of blood pressure.

Approach and results: Rap1b(-/-) mice developed cardiac hypertrophy and elevated blood pressure, but maintained a normal heart rate. Correcting elevated blood pressure with losartan, an angiotensin II type 1 receptor antagonist, alleviated cardiac hypertrophy in Rap1b(-/-) mice, suggesting a possibility that cardiac hypertrophy develops secondary to hypertension. The indices of renal function and plasma renin activity were normal in Rap1b(-/-) mice. Ex vivo, we examined whether the effect of Rap1b deletion on smooth muscle-mediated vessel contraction and endothelium-dependent vessel dilation, 2 major mechanisms controlling basal vascular tone, was the basis for the hypertension. We found increased contractility on stimulation with a thromboxane analog or angiotensin II or phenylephrine along with increased inhibitory phosphorylation of myosin phosphatase under basal conditions consistent with elevated basal tone and the observed hypertension. Cyclic adenosine monophosphate-dependent relaxation in response to Rap1 activator, Epac, was decreased in vessels from Rap1b(-/-) mice. Defective endothelial release of dilatory nitric oxide in response to elevated blood flow leads to hypertension. We found that nitric oxide-dependent vasodilation was significantly inhibited in Rap1b-deficient vessels.

Conclusions: This is the first report to indicate that Rap1b in both smooth muscle and endothelium plays a key role in maintaining blood pressure by controlling normal vascular tone.

Keywords: relaxation; signal transduction; vasodilation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Blood Pressure* / drug effects
  • Cardiomegaly / enzymology
  • Cardiomegaly / etiology
  • Cardiomegaly / genetics
  • Cardiomegaly / physiopathology
  • Cardiomegaly / prevention & control
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects
  • Endothelial Cells / enzymology*
  • Female
  • Humans
  • Hypertension / drug therapy
  • Hypertension / enzymology*
  • Hypertension / etiology
  • Hypertension / genetics
  • Hypertension / physiopathology
  • Male
  • Mice
  • Mice, Knockout
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / enzymology*
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / enzymology*
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • Phosphorylation
  • RNA Interference
  • Signal Transduction
  • Time Factors
  • Transfection
  • Vasoconstriction* / drug effects
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation* / drug effects
  • Vasodilator Agents / pharmacology
  • rap GTP-Binding Proteins / deficiency
  • rap GTP-Binding Proteins / genetics
  • rap GTP-Binding Proteins / metabolism*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Nitric Oxide
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • RAP1B protein, human
  • Rap1b protein, mouse
  • rap GTP-Binding Proteins